Finland's CurifyLabs has raised a $14m Series A to expand in the US, where pharmacies in 21 states use its 3D printers to make custom medicine doses.

The state Medical Board accused a doctor and pharmacist of improperly manufacturing weight loss drugs out of a Sorrento Valley pain clinic.

A major supplier of sterile hospital drugs is packing up operations in southwest Phoenix, and it is taking 116 paychecks with it. Central Admixture Pharmacy Services Inc. is shutting down its 503B ...

Central Admixture Pharmacy Services (CAPS) on June 25 informed state officials of its plans to close its Phoenix facility at ...

The new-age pharmaceutical landscape shows a growing reliance on customized, specialized therapies known to customers as compounded medicines. Compounding occurs when an approved and licensed ...

Discover how compounding pharmacies are transforming healthcare by creating tailor-made medications for patients with unique needs, offering critical alternatives when standard drugs fall short, and ...

Up to approximately 25,000 prescriptions per day in fulfillment capacity available under the agreement, with reach across all U.S. states Strengthens the Company's U.S. supply chain and regulatory ...

In investing, compounding involves reinvesting the earnings an asset generates so they produce additional gains over time. Compounding is a powerful investment tool because it not only provides gains ...

FDA proposes excluding blockbuster weight-loss drugs from 503B compounding list Move could limit bulk production by outsourcing facilities Novo and Lilly support FDA stance If finalized, the move ...

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...

The Food and Drug Administration is taking the first step toward potentially allowing compounding pharmacies to produce seven peptides that are currently restricted because of the agency’s previous ...

April 1 (Reuters) - The U.S. Food and Drug Administration on Wednesday clarified its policies on compounded versions of popular GLP-1 drugs, signaling tighter limits on their production as national ...